Recital 5, Regulation (EU) 2023/2594

In forcesince 21 Nov 2023

However, in a letter dated 14 July 2022 addressed to the Commission, the applicant indicated that it was not willing to generate new data as requested by the Authority. In reply to that letter, the Commission clarified in a letter dated 8 November 2022 that a renewal of the authorisation of the preparation of robenidine hydrochloride (Cycostat 66G) could not be granted, should the Authority’s opinion raise safety concerns due to a lack of required information and data. The applicant did not modify its position afterwards.